Abbott announces CE Mark and European launch of next-generation XIENCE Xpedition™ Drug Eluting Stent
20 August 2012 | By Abbott
XIENCE Xpedition™ Everolimus Eluting Coronary Stent System receives CE Mark...
List view / Grid view
20 August 2012 | By Abbott
XIENCE Xpedition™ Everolimus Eluting Coronary Stent System receives CE Mark...
17 August 2012 | By HORIBA Scientific
Fully automated extended wavelength range capability and new generation of software offer versatility without compromise...
17 August 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta® (linagliptin) tablets for use as add-on therapy to insulin.
17 August 2012 | By Biogen Idec
New collaboration in support of Science, Technology, Engineering, and Math education...
15 August 2012 | By Phenomenex
Fasha Mahjoor, founder and CEO of Phenomenex, will leap off the 87th floor of The Shard in London on the 3rd of September...
15 August 2012 | By Maitland
Study to test Debio 0932 in patients with advanced non-small cell lung cancer...
15 August 2012 | By Novartis
Results of two Phase III studies...
15 August 2012 | By Bristol-Myers Squibb Company
Patient management programs for Sprycel® patients launched...
15 August 2012 | By GlaxoSmithKline
GSK has reached agreement to divest the majority of its “Classic Brands” in Australia...
14 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has grown again in the current financial year...
13 August 2012 | By Patheon
Patheon Inc. announced that Mark J. Kontny is no longer with the company...
13 August 2012 | By Sanofi
Breakthrough device design talks patients and caregivers through the injection process...
13 August 2012 | By Abbott
40 students living with CF each to receive a $2,500 CFCareForward Scholarship...
13 August 2012 | By Roche
First major treatment advance in more than 25 years for sight-threatening condition...
13 August 2012 | By AstraZeneca
NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval...